Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R. Fridrik MA, et al. Among authors: greil r. Ann Hematol. 2010 Mar;89(3):273-82. doi: 10.1007/s00277-009-0811-x. Epub 2009 Aug 20. Ann Hematol. 2010. PMID: 19693500 Clinical Trial.
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T. Fridrik MA, et al. Among authors: greil r. Ann Hematol. 1997 Oct;75(4):135-40. doi: 10.1007/s002770050330. Ann Hematol. 1997. PMID: 9402845 Clinical Trial.
Hodgkin lymphoma in Tyrol-a population-based study.
Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A. Fong D, et al. Among authors: greil r. Ann Hematol. 2009 May;88(5):449-56. doi: 10.1007/s00277-008-0618-1. Epub 2008 Oct 10. Ann Hematol. 2009. PMID: 18846373
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R; Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators. Jäger U, et al. Among authors: greil r. Haematologica. 2012 Sep;97(9):1431-8. doi: 10.3324/haematol.2011.059246. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511498 Free PMC article. Clinical Trial.
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M. Thaler J, et al. Among authors: greil r. Leuk Res. 1997 Jan;21(1):75-80. doi: 10.1016/s0145-2126(96)00084-7. Leuk Res. 1997. PMID: 9029189 Clinical Trial.
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Hilbe W, et al. Among authors: greil r. Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8. doi: 10.3109/10428190109097753. Leuk Lymphoma. 2001. PMID: 11911409 Clinical Trial.
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group. Kühr T, et al. Among authors: greil r. Leuk Res. 2003 May;27(5):405-11. doi: 10.1016/s0145-2126(02)00223-0. Leuk Res. 2003. PMID: 12620292 Clinical Trial.
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia; Czech Leukemia Study Group for Life; CELL. Fiegl M, et al. Among authors: greil r. Ann Hematol. 2011 Sep;90(9):1083-91. doi: 10.1007/s00277-011-1192-5. Epub 2011 Feb 25. Ann Hematol. 2011. PMID: 21350830
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.
Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J. Hilbe W, et al. Among authors: greil r. Leuk Res. 1998 Oct;22(10):881-6. doi: 10.1016/s0145-2126(98)00064-2. Leuk Res. 1998. PMID: 9766747
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL. Fiegl M, et al. Among authors: greil r. Ann Hematol. 2014 Feb;93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30. Ann Hematol. 2014. PMID: 24292560 Clinical Trial.
665 results